{"id":65780,"date":"2026-05-20T12:34:21","date_gmt":"2026-05-20T04:34:21","guid":{"rendered":"https:\/\/flcube.com\/?p=65780"},"modified":"2026-05-20T12:34:22","modified_gmt":"2026-05-20T04:34:22","slug":"shandong-buchang-pharmaceuticals-secures-exclusive-license-for-kyn003-broad-spectrum-influenza-vaccine-through-strategic-partnership-with-hefei-keyinuo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65780","title":{"rendered":"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo"},"content":{"rendered":"\n<p><strong>Shandong Buchang Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603858:SHA\">SHA: 603858<\/a>) announced today a comprehensive <strong>licensing agreement<\/strong> with fellow Chinese firm <strong>Hefei Keyinuo Biotechnology Co., Ltd.<\/strong> for <strong>KYN003<\/strong>, a <strong>seasonal broad-spectrum influenza vaccine<\/strong> for human use. The deal combines an <strong>equity investment<\/strong> with an <strong>exclusive technology license<\/strong>, establishing a new joint venture entity and securing extensive commercial rights across global markets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Shandong Buchang Pharmaceuticals (SHA: 603858), Hefei Keyinuo Biotechnology<\/td><\/tr><tr><td><strong>Subsidiaries Involved<\/strong><\/td><td>Huapai Bio, Tianyuan Bio (Buchang); Nanjing Keyinuo (new JV)<\/td><\/tr><tr><td><strong>Equity Stake<\/strong><\/td><td>Huapai Bio holds 11.11% stake in newly formed Nanjing Keyinuo<\/td><\/tr><tr><td><strong>Licensed Product<\/strong><\/td><td>KYN003 seasonal broad-spectrum influenza vaccine<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 12 million (USD 1.76 million)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to RMB 28 million (USD 4.1 million)<\/td><\/tr><tr><td><strong>Royalty Structure<\/strong><\/td><td>Tiered royalties based on annual net sales post-launch<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-intellectual-property-amp-territory-rights\">Intellectual Property &amp; Territory Rights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IP Contribution:<\/strong> Hefei Keyinuo contributes complete seasonal broad-spectrum flu vaccine pipeline, including patents, proprietary technologies, and trade secrets as in-kind intangible asset to Nanjing Keyinuo<\/li>\n\n\n\n<li><strong>Licensed Territory:<\/strong> China (mainland, Hong Kong, Macau, Taiwan) plus all countries outside reserved territories<\/li>\n\n\n\n<li><strong>Reserved Territories:<\/strong> European Union, United States, Canada, United Kingdom, and Japan retained by Hefei Keyinuo<\/li>\n\n\n\n<li><strong>License Type:<\/strong> Exclusive license granted to Tianyuan Bio for licensed territory<\/li>\n\n\n\n<li><strong>Responsibilities:<\/strong> Tianyuan Bio assumes full responsibility for R&amp;D, manufacturing, regulatory filings, and commercialization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-opportunity\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Influenza Vaccine Market<\/strong><\/td><td>Global market projected to reach $8.5 billion by 2028, with broad-spectrum vaccines representing next-generation opportunity<\/td><\/tr><tr><td><strong>Technology Differentiation<\/strong><\/td><td>Seasonal broad-spectrum approach addresses multiple influenza strains simultaneously, potentially improving efficacy over traditional strain-specific vaccines<\/td><\/tr><tr><td><strong>Geographic Strategy<\/strong><\/td><td>Comprehensive coverage of China and emerging markets provides significant commercial runway while respecting Hefei Keyinuo&#8217;s retained rights in major developed markets<\/td><\/tr><tr><td><strong>Vertical Integration<\/strong><\/td><td>Buchang leverages existing manufacturing and commercial infrastructure through Tianyuan Bio for rapid market entry<\/td><\/tr><tr><td><strong>Risk Mitigation<\/strong><\/td><td>Milestone-based payment structure aligns financial obligations with development progress and regulatory success<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Potential Deal Value:<\/strong> Up to RMB 40 million (USD 5.86 million) including upfront and milestones<\/li>\n\n\n\n<li><strong>Revenue Model:<\/strong> Long-term royalty stream from tiered net sales provides ongoing returns<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Equity investment combined with licensing provides asset-light access to innovative vaccine platform<\/li>\n\n\n\n<li><strong>Balance Sheet Impact:<\/strong> Modest upfront commitment with scalable investment tied to program success<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, development timelines, regulatory approvals, and commercial expectations for KYN003. Actual results may differ materially due to risks including clinical development challenges, regulatory decisions, manufacturing complexities, and competitive dynamics in the influenza vaccine market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603858_20260520_QTLO.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603858_20260520_QTLO.\"><\/object><a id=\"wp-block-file--media-97d3ffeb-532d-4181-ae0a-8df1c032c63a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603858_20260520_QTLO.pdf\">603858_20260520_QTLO<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603858_20260520_QTLO.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-97d3ffeb-532d-4181-ae0a-8df1c032c63a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[280,4747,1103],"class_list":["post-65780","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-buchang-pharmaceuticals","tag-keyinuo-biotechnology","tag-sha-603858"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow Chinese firm Hefei Keyinuo Biotechnology Co., Ltd. for KYN003, a seasonal broad-spectrum influenza vaccine for human use. The deal combines an equity investment with an exclusive technology license, establishing a new joint venture entity and securing extensive commercial rights across global markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo\" \/>\n<meta property=\"og:description\" content=\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow Chinese firm Hefei Keyinuo Biotechnology Co., Ltd. for KYN003, a seasonal broad-spectrum influenza vaccine for human use. The deal combines an equity investment with an exclusive technology license, establishing a new joint venture entity and securing extensive commercial rights across global markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65780\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T04:34:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-20T04:34:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65780\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo\",\"datePublished\":\"2026-05-20T04:34:21+00:00\",\"dateModified\":\"2026-05-20T04:34:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65780\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Buchang Pharmaceuticals\",\"Keyinuo Biotechnology\",\"SHA: 603858\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65780#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65780\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65780\",\"name\":\"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-20T04:34:21+00:00\",\"dateModified\":\"2026-05-20T04:34:22+00:00\",\"description\":\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow Chinese firm Hefei Keyinuo Biotechnology Co., Ltd. for KYN003, a seasonal broad-spectrum influenza vaccine for human use. The deal combines an equity investment with an exclusive technology license, establishing a new joint venture entity and securing extensive commercial rights across global markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65780\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow Chinese firm Hefei Keyinuo Biotechnology Co., Ltd. for KYN003, a seasonal broad-spectrum influenza vaccine for human use. The deal combines an equity investment with an exclusive technology license, establishing a new joint venture entity and securing extensive commercial rights across global markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65780","og_locale":"en_US","og_type":"article","og_title":"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo","og_description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow Chinese firm Hefei Keyinuo Biotechnology Co., Ltd. for KYN003, a seasonal broad-spectrum influenza vaccine for human use. The deal combines an equity investment with an exclusive technology license, establishing a new joint venture entity and securing extensive commercial rights across global markets.","og_url":"https:\/\/flcube.com\/?p=65780","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-20T04:34:21+00:00","article_modified_time":"2026-05-20T04:34:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65780#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65780"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo","datePublished":"2026-05-20T04:34:21+00:00","dateModified":"2026-05-20T04:34:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65780"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Buchang Pharmaceuticals","Keyinuo Biotechnology","SHA: 603858"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65780#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65780","url":"https:\/\/flcube.com\/?p=65780","name":"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-20T04:34:21+00:00","dateModified":"2026-05-20T04:34:22+00:00","description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today a comprehensive licensing agreement with fellow Chinese firm Hefei Keyinuo Biotechnology Co., Ltd. for KYN003, a seasonal broad-spectrum influenza vaccine for human use. The deal combines an equity investment with an exclusive technology license, establishing a new joint venture entity and securing extensive commercial rights across global markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65780"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65780"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65780\/revisions"}],"predecessor-version":[{"id":65783,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65780\/revisions\/65783"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}